Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

(HealthDay News) — Myelodysplastic syndrome (MDS) is independently associated with incident cardiovascular disease (CVD), according to a study published online Nov. 10 in the Canadian Journal of ...

In this retrospective analysis, researchers aimed to evaluate outcomes of continuing next-generation ALK TKIs plus chemotherapy after progression on TKI monotherapy in patients with ALK-positive NSCLC ...

In this study, researchers estimated results for 100% lung cancer screening uptake by all unscreened but screening-eligible individuals.

In this study, researchers evaluated the dose-response relationship between body mass index and the risk of developing pancreatic cancer by the age of 50 years.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy.

Investigators assessed PSA response to treatment at various time points for their relative abilities to predict disease progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC ...

In the phase 3 HER2CLIMB-02 trial, researchers evaluated the efficacy and safety of tucatinib plus T-DM1 compared to T-DM1 alone in HER2+ locally advanced or metastatic breast cancer.

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

In this systematic review, researchers examined the clinical features, diagnosis, treatment, and prognosis of pregnancy-associated colorectal cancer.

Status quo of choice between colonoscopy and FIT was cost-effective for White adults; CTC was cost-saving versus no screening.

Cancer related cognitive impairment in patients can stem from the cancer itself as well as the therapies used to treat it.